4D Molecular Therapeutics Inc (FDMT) — Capital Reinvestment Ratio
Latest as of December 2025:
0.02x
4D Molecular Therapeutics Inc (FDMT) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow ($28.55 Million) in capital expenditures ($631.00K). See 4D Molecular Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
$28.55 Million
USD
Capital Expenditures
$631.00K
USD
Data as of
Dec 2025
Most recent filing
4D Molecular Therapeutics Inc Capital Reinvestment Ratio (2017–2017)
This chart tracks 4D Molecular Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for 4D Molecular Therapeutics Inc (2017–2017)
Year-by-year Capital Reinvestment Ratio for 4D Molecular Therapeutics Inc from 2017 to 2017. For live market cap and broader valuation context, see FDMT market cap.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2017 | 0.07x | $8.24 Million | $573.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow